RxDoctor Payments Data

Mark Clinger, MD

Family Medicine · Nampa, IDNPI 1699769471

Payments from drug & device makers

$2,473in general payments, 2019–2025

Across 140 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$454
  • Amgen$342
  • AstraZeneca$264
  • Pfizer$238
  • Abbott$184
  • Novo Nordisk$96
  • plus $894 from 22 others

What the payments were for

  • Food & beverage$2,473100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,473 in reported general payments places this provider in the 85th percentile of 803 family medicine providers in Idaho.

See all family medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$8,390
Medicare patients
44
Services billed
234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin26$43,850
EliquisApixaban29$41,493
TrulicityDulaglutide12$15,060
XareltoRivaroxaban16$14,128
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$13,695
Solifenacin Succinate15$3,351
Atorvastatin Calcium175$2,095
Gabapentin52$2,051
Omeprazole91$1,717
Albuterol Sulfate HfaAlbuterol Sulfate48$1,671
Levothyroxine Sodium120$1,343
Potassium Chloride37$897
Amlodipine Besylate115$811
Losartan Potassium78$786
Glipizide ErGlipizide42$775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$56$43,85026 claims
PfizerEliquis$238$41,49329 claims
Lilly USA, LLCTrulicity$79$15,06012 claims
Johnson & JohnsonXarelto$13$14,12816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 803 family medicine providers in Idaho.

Other family medicine in Nampa

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →